Carcinoma, Renal Cell: all 1,992 studies
Page 13 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.
- Volume 3D_US KidneyCompletedNCT03841149
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT03829436Phase 1
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCompletedNCT03829111Phase 1
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
- Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1
- Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompletedNCT03798626Phase 1
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
- Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsCompletedNCT03776123
- A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsCompletedNCT03775850Phase 1
- IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedNCT03758781Phase 1
- PD-L1 Expression in Japanese Renal Cell Carcinoma PatientsCompletedNCT03748901
- Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.CompletedNCT03744585
- 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular InvolvementStatus unknownNCT03738488Not applicable
- Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell CarcinomaStatus unknownNCT03734614
- Spontaneous Regression in Metastatic Melanoma and Renal Cell CarcinomaActive, not recruitingNCT03728842
- Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCCompletedNCT03699579
- A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKCompletedNCT03696407
- SAbR For Oligo-Progressive Renal Cell Cancer.CompletedNCT03696277Phase 2
- Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular BiomarkersStatus unknownNCT03694912
- A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3
- Role of Geminin and Mcm-2 in Prognosis of Renal Cell CarcinomaStatus unknownNCT03692533Not applicable
- INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell CarcinomaTerminatedNCT03692338Not applicable
- ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)CompletedNCT03685448Phase 2
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
- Surgical Treatment of Pancreatic RCC MetastasesCompletedNCT03670992
- Non-Invasive Diagnostics of Small Renal MassesStatus unknownNCT03667885
- A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has SpreadCompletedNCT03663946
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminatedNCT03655613Phase 1/2
- Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingNCT03647878
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive, not recruitingNCT03647163Phase 1/2
- Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesStatus unknownNCT03638206Phase 1/2
- Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid TumorsTerminatedNCT03637803Phase 1/2
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Active, not recruitingNCT03634540Phase 2
- Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineCompletedNCT03633110Phase 1/2
- Safety and Compliance of Renal Cancer Patients Treated by Non-IV DrugsStatus unknownNCT03630692
- TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research InitiativeCompletedNCT03630536
- A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedNCT03629756Phase 1
- BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)Status unknownNCT03628859
- Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell CarcinomaActive, not recruitingNCT03624673Not applicable
- Optimizing the Management of Patients With Oral TherapyTerminatedNCT03623490Not applicable
- Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CTStatus unknownNCT03616951
- Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneCompletedNCT03602079Phase 1/2
- PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell CarcinomaWithdrawnNCT03598816Phase 2
- Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line AxitinibStatus unknownNCT03592199Phase 2
- NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyActive, not recruitingNCT03589339Phase 1
- Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT03587662Phase 2
- Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell CarcinomaSuspendedNCT03575611Phase 2
- Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer ParticipantsCompletedNCT03568435
- 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSECompletedNCT03556046Phase 1
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.TerminatedNCT03549000Phase 1
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
- Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney CancerWithdrawnNCT03540199Phase 2
- Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial NephrectomyWithdrawnNCT03528057Not applicable
- Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03519542
- Effects of Anesthesia on Immunity in CancerCompletedNCT03514550Phase 4
- CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid TumorsCompletedNCT03511391Phase 2
- High Dose IL 2 and Entinostat in RCCActive, not recruitingNCT03501381Phase 2
- Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney CancerCompletedNCT03473730Early Phase 1
- Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell CarcinomaCompletedNCT03471897
- Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaCompletedNCT03469713Phase 2
- A Study of BCD-135 in Patients With Advanced Solid TumorsStatus unknownNCT03464032Phase 1
- A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaCompletedNCT03463681Phase 2
- Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerCompletedNCT03455452
- CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedNCT03454451Phase 1
- Prior Axitinib as a Determinant of Outcome of Renal SurgeryActive, not recruitingNCT03438708Phase 2
- CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell CarcinomaCompletedNCT03427476Phase 1
- Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaCompletedNCT03419572
- Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell CarcinomaTerminatedNCT03409224
- Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted TherapiesTerminatedNCT03408652Phase 3
- Social Media Listening in Improving Clinical Trial Recruitment in Patients With CancerWithdrawnNCT03408561Not applicable
- Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell CarcinomaCompletedNCT03395379
- Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell CarcinomaTerminatedNCT03393936Phase 1/2
- Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal CancerWithdrawnNCT03390413Not applicable
- Testosterone in Metastatic Renal Cell Carcinoma PatientsCompletedNCT03379012Phase 2
- Mix Vaccine for Metastatic Kidney CancerCompletedNCT03357289Phase 1/2
- caBozantinib in cOllectiNg ductS Renal Cell cArcInomaCompletedNCT03354884Phase 2
- A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid TumorsTerminatedNCT03343613Phase 1
- Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
- Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1
- Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell CarcinomaWithdrawnNCT03323710Phase 2
- Study of Durvalumab and Guadecitabine in Advanced Kidney CancerActive, not recruitingNCT03308396Phase 1/2
- Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaActive, not recruitingNCT03291028
- Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingNCT03284385Phase 2
- Denosumab and Pembrolizumab in Clear Cell Renal CarcinomaStatus unknownNCT03280667Phase 2
- RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCCStatus unknownNCT03259477Not applicable
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- TRACERx Renal CAPTURE Sub-studyStatus unknownNCT03226886
- Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCCWithdrawnNCT03226236Phase 2
- Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)Status unknownNCT03218319Not applicable
- Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1
- Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell CarcinomasWithdrawnNCT03189186Phase 1
- Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2
- Evaluation of Pathway Modulation by Raf, MEK, & Kinase InhibitorsCompletedNCT03176485Not applicable
- Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
- A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has SpreadCompletedNCT03161145